Proactive Investors - Run By Investors For Investors

Canntab Therapeutics teams up with orthopedic surgeon for cannabis tablet trial

A placebo-controlled study led by Dr Don Garbuz will test the effectiveness of the company’s Canntab product in reducing the need for opioids after knee-replacement surgery
A greenhouse with marijuana plants
Canntab plans to create tablets for the study with Toronto-based FSD Pharma

Canntab Therapeutics Ltd (CSE:PILL) (OTCMKTS:TLFTF) said Wednesday that it is teaming up with Dr Don Garbuz, an orthopedic surgeon, to study the effectiveness of the company’s Canntab tablets in reducing the need for opioids after knee-replacement surgery.

The Toronto-based company said in a press release that it’s seeking approval from the university to conduct a randomized, double-blind, placebo-controlled clinical trial, with Garbuz as lead investigator.

READ: Canntab Therapeutics wants to grow awareness of the cannabis group in Canada and elsewhere

Shares of Canntab climbed C$0.07 to C$1.12 in Wednesday's Canadian trading.

Garbuz is head of the division of lower limb reconstruction and oncology at the University of British Columbia’s division of orthopedics.

Canntab plans to create the tablets for the study with Toronto-based FSD Pharma Inc (OTCMKTS:FSDDF), a licensed producer under the Access to Cannabis for Medical Purposes Regulations.

“This study will help advance our understanding of the potential effects of cannabis as a treatment for pain and will become the basis for conducting future cannabinoid and pain management clinical trials," Garbuz said in a statement. "This important study aims to help us better understand the potential impact of cannabis as an alternative for opioids, so that patients might face better outcomes."

It’s not unusual for patients to misuse opioids after surgery, with nearly 5% of “previously opiate-naive patients” becoming chronic abusers, Canntab said in the press release.

The total cost of the study is estimated at C$600,000, with an anticipated time frame of 12 to 18 months.

 

Contact Dennis Fitzgerald at [email protected]

Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here
View full PILL profile View Profile

Canntab Therapeutics Ltd Timeline

Related Articles

cannabis bud on tray
April 25 2019
Armed with a new partnership with Canada's largest pharmacy and an international cultivator, Flowr is aiming to provide medicinal and recreational consumers around the world with premium, high-quality cannabis
Sydney Harbour Bridge
January 22 2019
A phase I study in Australia is evaluating a cannabis spray therapeutic in cancer patients.
FSD Pharma facility
June 11 2019
The indoor hydroponic facility will be optimized for large-scale, medical-grade cannabis production and once complete, is expected to have over 3.9 million sq/ft available for production
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use